Pfizer is considering selling its consumer healthcare ... brands – multivitamin tablets Centrum and headache pill Advil. Germany’s Merck KGaA is also considering divesting its non-prescription ...

The consumer health business was essentially a partnership between GSK and Pfizer, formed in 2019 ... (e.g. Centrum), pain relief (e.g. Pandol, Advil), respiratory health (e.g. Otrivin, Flonase ...

The British consumer-healthcare business--which was spun out of GSK and is partly owned by Pfizer--said Thursday ... the-counter medicines Panadol and Advil--posted organic revenue growth of ...

Advil is benefitting from our ongoing investment ... with over 85% of this being bought from Pfizer. Turning now to our 2024 guidance. Based on our good year-to-date performance and momentum ...

Pfizer axed 80 Kansas employees in the second round of cuts ... and identifies “certified inclusive” brands like The Honey Pot, Theraflu, Ritual, Thinx, Advil, Always, DIVA, Colgate, Voltaren, and ...

Research on the Moderna or Pfizer-BioNTech vaccines did not ask trial ... The CDC advises against using over-the-counter (OTC) pain relievers like Advil (ibuprofen), aspirin, or Tylenol ...

The 10-year PRECISION trial, which Pfizer funded and designed, compared the safety of COX-2 inhibitor celecoxib (Celebrex) with nonsteroidal anti-inflammatory drugs ibuprofen and naproxen.

The National Multiple Sclerosis Society also recommends that people with MS get vaccinated against COVID-19—preferably with Pfizer-BioNTech ... medication, such as Advil (ibuprofen) or Tylenol ...

The protein subunit-based Novavax vaccine is an alternative to the Pfizer and Moderna vaccines ... With that said, some people may be tempted to take aspirin, Advil (ibuprofen), or some other ...

Paxlovid on its own drove much of Pfizer’s total sales (PDF) haul of $17.7 billion, up 32% year-over-year. Taking out COVID revenues, the company pulled $13.6 billion in sales in a 14% jump ...

Pfizer (NYSE: PFE) is scheduled to report its Q3 2024 results on Tuesday, October 29. We expect the company to post revenue of $15.1 billion and earnings of $0.63 on a per share and adjusted basis ...

Paxlovid sales surge to $2.7 billion, beating expectations Pfizer raises annual revenue forecast for COVID products to $10.5 billion Pfizer management faces pressure from activist hedge fund ...